La Revue de medecine interne · 2026
[Acute intermittent porphyria: When diagnostic errance jeopardizes patient health].
Аннотация на английскомСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Labarthe Guillaume, Galinier Anne, Rulquin Florence, Pavy Le Traon Anne, Maquet Julien, Jamme Thibaut
Аннотация
INTRODUCTION: Acute intermittent porphyria is a rare genetic disorder characterized by an enzyme deficiency in heme synthesis, causing an accumulation of neurotoxic precursors. Its clinical symptoms include abdominal and/or lumbar pain, reddish-brown urine, and neuropsychiatric signs.
OBSERVATION: We report the case of a young female patient who presented with several episodes of intense low back pain followed by confusion, visual hallucinations, epileptic seizures, and severe dysautonomia with hypotension and impaired alertness. The diagnosis was established after several weeks of investigation, one year after the onset of symptoms. The course of the disease was marked by an early relapse without any triggering factor, which led to treatment with givosiran, which was spectacularly successful. Treatment-induced hyperhomocysteinemia was successfully corrected with pyridoxine.
CONCLUSION: It is essential to be aware of the epidemiology, risk factors, and suggestive symptoms of this potentially serious treatable disease to reduce diagnostic uncertainty, limit long-term complications, and improve prognosis.
OBSERVATION: We report the case of a young female patient who presented with several episodes of intense low back pain followed by confusion, visual hallucinations, epileptic seizures, and severe dysautonomia with hypotension and impaired alertness. The diagnosis was established after several weeks of investigation, one year after the onset of symptoms. The course of the disease was marked by an early relapse without any triggering factor, which led to treatment with givosiran, which was spectacularly successful. Treatment-induced hyperhomocysteinemia was successfully corrected with pyridoxine.
CONCLUSION: It is essential to be aware of the epidemiology, risk factors, and suggestive symptoms of this potentially serious treatable disease to reduce diagnostic uncertainty, limit long-term complications, and improve prognosis.